Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan

mAbs

Volumn 11, Issue 6, 2019, Pages 987-995

  Goldenberg, David M ^a   Sharkey, Robert M ^a  

^a CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

Author keywords

Antibody drug conjugate; IMMU 132; sacituzumab govitecan; SN 38; TROP 2

Indexed keywords

ANTIBODY DRUG CONJUGATE; ANTINEOPLASTIC AGENT; BAT 8003; DS 1062A; FIRTECAN; MEMBRANE ANTIGEN; PF 06664178; RN 927C; SACITUZUMAB GOVITECAN; TROPHOBLAST CELL SURFACE ANTIGEN 2; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE; CAMPTOTHECIN; CELL ADHESION MOLECULE; IRINOTECAN; MONOCLONAL ANTIBODY; TACSTD2 PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR PROTEIN;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL PRACTICE; DRUG APPROVAL; DRUG DESIGN; HUMAN; LUNG CANCER; NONHUMAN; PROTEIN TARGETING; TRIPLE NEGATIVE BREAST CANCER; TUMOR MICROENVIRONMENT; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECT; FEMALE; MALE; METABOLISM; NEOPLASM; PATHOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC);

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, NEOPLASM; CAMPTOTHECIN; CELL ADHESION MOLECULES; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; IMMUNOCONJUGATES; IRINOTECAN; MALE; NEOPLASM PROTEINS; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 85070348417     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2019.1632115     Document Type: Article

References (67)

1. Sievers EL, Senter PD., Antibody-drug conjugates in cancer therapy. Annu Rev Med. 2013;64:15–29. doi:10.1146/annurev-med-050311-201823.
2. Leal M, Sapra P, Hurvitz SA, Senter P, Wahl A, Schutten M, Shah, D.K., Haddish‐Berhane, N., and Kabbarah, O., Antibody-drug conjugates: an emerging modality for the treatment of cancer. Ann N Y Acad Sci. 2014;1321:41–54. doi:10.1111/nyas.12499.
3. Govindan SV, Sharkey RM, Goldenberg DM., Prospects and progress of antibody-drug conjugates in solid tumor therapies. Expert Opin Biol Ther. 2016;16:883–93. doi:10.1517/14712598.2016.1173203.
4. Abdollahpour-Alitappeh M, Lotfinia M, Gharibi T, Mardaneh J, Farhadihosseinabadi B, Larki P, Faghfourian B, Sepehr KS, Abbaszadeh-Goudarzi K, Abbaszadeh-Goudarzi G, et al. Antibody-drug conjugates (ADCs) for cancer therapy: strategies, challenges, and successes. J Cell Physiol. 2019;234:5628–42. doi:10.1002/jcp.27419.
5. Birrer MJ, Moore KN, Betella I, Bates RC. in press. Antibody-drug conjugate-based therapeutics: state of the Science. J Natl Cancer Inst. 2019 Mar 11. pii: djz035. doi:10.1093/jnci/djz035. [Epub ahead of print]
6. Ricart AD. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin Cancer Res. 2011;17:6417–27.
7. Alley SC, Okeley NM, Senter PD. Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol. 2010;14:529–37.
8. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram, M, Oh, DY, Diéras, V, and Guardino, E, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783–91.
9. Moore KN, Vergote I, Oaknin A, Colombo N, Banerjee S, Oza A, Pautier, P, Malek, K, and Birrer, MJ. FORWARD I: A Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer. Future Oncol. 2018;14:1669–78.
10. Hamblett KJ, Senter PD, Chace DF, Sun MM, Lenox J, Cerveny CG, Kissler, KM, Bernhardt, SX, Kopcha, AK, Zabinski, RF, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res. 2004;10:7063–70. doi:10.1158/1078-0432.CCR-04-0789.
11. Strop P, Delaria K, Foletti D, Witt JM, Hasa-Moreno A, Poulsen K, Casas, MG, Dorywalska, M, Farias, S, Pios, A, et al. Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading. Nat Biotechnol. 2015;33:694–96.
12. Carter PJ, Senter PD. Antibody-drug conjugates for cancer therapy. Cancer J. 2008;14:154–69. doi:10.1097/PPO.0b013e318172d704.
13. Goldenberg DM, Cardillo TM, Govindan SV, Rossi EA, Sharkey RM. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). Oncotarget. 2015;6:22496–512. doi:10.18632/oncotarget.4318.
14. Goldenberg DM, Stein R, Sharkey RM. The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target. Oncotarget. 2018;9:28989–9006. doi:10.18632/oncotarget.25615.
15. Lipinski M, Parks DR, Rouse RV, Herzenberg LA. Human trophoblast cell-surface antigens defined by monoclonal antibodies. Proc Natl Acad Sci USA. 1981;78:5147–50. doi:10.1073/pnas.78.8.5147.
16. Cubas R, Li M, Chen C, Yao Q. Trop2: A possible therapeutic target for late stage epithelial carcinomas. Biochim Biophys Acta. 2009;1796:309–14. doi:10.1016/j.bbcan.2009.08.001.
17. Shvartsur A, Bonavida B. Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications. Genes Cancer. 2015;6:84–105. doi:10.18632/genesandcancer.40.
18. Stein R, Basu A, Chen S, Shih LB, Goldenberg DM. Specificity and properties of MAb RS7-3G11 and the antigen defined by this pancarcinoma monoclonal antibody. Int J Cancer. 1993;55:938–46.
19. Basu A, Goldenberg DM, Stein R. The epithelial/carcinoma antigen EGP-1, recognized by monoclonal antibody RS7-3G11, is phosphorylated on serine 303. Int J Cancer. 1995;62:472–79.
20. Stein R, Basu A, Goldenberg DM, Lloyd KO, Mattes MJ. Characterization of cluster 13: the epithelial/carcinoma antigen recognized by MAb RS7. Int J Cancer Suppl. 1994;8:98–102.
21. De Leij L, Helrich W, Stein R, Mattes MJ. SCLC-cluster-2 antibodies detect the pancarcinoma/epithelial glycoprotein EGP-2. Int J Cancer Suppl. 1994;8:60–63.
22. Shih LB, Xuan H, Aninipot R, Stein R, Goldenberg DM. In vitro and in vivo reactivity of an internalizing antibody, RS7, with human breast cancer. Cancer Res. 1995;55:5857s–63s.
23. Cardillo TM, Govindan SV, Sharkey RM, Trisal P, Arrojo R, Liu D, Rossi EA, Chang C-H, Goldenberg DM. Sacituzumab govitecan (IMMU-132), an anti-Trop-2/SN-38 antibody-drug conjugate: characterization and efficacy in pancreatic, gastric, and other cancers. Bioconjug Chem. 2015;26:919–31. doi:10.1021/acs.bioconjchem.5b00223.
24. Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, Sparreboom A. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res. 2001;7:2182–94.
25. Garcia-Carbonero R, Supko JG. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res. 2002;8:641–61.
26. Moon SJ, Govindan SV, Cardillo TM, D’Souza CA, Hansen HJ, Goldenberg DM. Antibody conjugates of 7-ethyl-10-hydroxycamptothecin (SN-38) for targeted cancer chemotherapy. J Med Chem. 2008;51:6916–26. doi:10.1021/jm800719t.
27. Govindan SV, Cardillo TM, Moon SJ, Hansen HJ, Goldenberg DM. CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates. Clin Cancer Res. 2009;15:6052–61. doi:10.1158/1078-0432.CCR-09-0586.
28. Govindan SV, Cardillo TM, Goldenberg DM. Chapter 8: topoisomerase inhibitors as antibody-drug conjugate payloads. In: Thurston DE, Jackson PJM, editors. Cytotoxic payloads for antibody-drug conjugates. Cambridge (UK): Royal Society of Chemistry; 2019. p. 164–84.
29. Cardillo TM, Govindan SV, Sharkey RM, Trisal P, Goldenberg DM. Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. Clin Cancer Res. 2011;17:3157–69. doi:10.1158/1078-0432.CCR-10-2939.
30. Sharkey RM, McBride WJ, Cardillo TM, Govindan SV, Wang Y, Rossi EA, Chang C-H, Goldenberg DM. Enhanced delivery of SN-38 to human tumor xenografts with an anti-Trop-2-SN-38 antibody conjugate (sacituzumab govitecan). Clin Cancer Res. 2015;21:5131–38. doi:10.1158/1078-0432.CCR-15-0670.
31. Bignotti E, Ravaggi A, Romani C, Falchetti M, Lonardi S, Facchetti F, Pecorelli S, Varughese J, Cocco E, Bellone S, et al. Trop-2 overexpression in poorly differentiated endometrial endometrioid carcinoma: implications for immunotherapy with hRS7, a humanized anti-trop-2 monoclonal antibody. Int J Gynecol Cancer. 2011;21:1613–21. doi:10.1097/IGC.0b013e318228f6da.
32. Raji R, Guzzo F, Carrara L, Varughese J, Cocco E, Bellone S, Betti, M, Todeschini, P, Gasparrini, S, Ratner, E, et al. Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody. J Exp Clin Cancer Res. 2011;30:106. doi:10.1186/1756-9966-30-24.
33. Varughese J, Cocco E, Bellone S, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Buza N, Pecorelli S, et al. Cervical carcinomas overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody. Am J Obstet Gynecol. 2011;205:567.e1-7. doi:10.1016/j.ajog.2011.06.093.
34. Lin H, Zhang H, Wang J, Lu M, Zheng F, Wang C, Tang X, Xu N, Chen R, Zhang D, et al. A novel human Fab antibody for Trop2 inhibits breast cancer growth in vitro and in vivo. Int J Cancer. 2014;134:1239–49. doi:10.1002/ijc.28451.
35. Liu J, Yang D, Yin Z, Gao M, Tong H, Su Y, Zhu, J, Ye, C, and Zhang, H, et al. A novel human monoclonal Trop2-IgG antibody inhibits ovarian cancer growth in vitro and in vivo. Biochem Biophys Res Commun. 2019 Apr 30;512(2):276–282. doi:10.1016/j.bbrc.2019.03.028. Epub 2019 Mar 14.
36. Mao Y, Wang X, Zheng F, Wang C, Tang Q, Tang X, Xu N, Zhang H, Zhang D, Xiong L, et al. The tumor-inhibitory effectiveness of a novel anti-Trop2 Fab conjugate in pancreatic cancer. Oncotarget. 2016;7:24810–23. doi:10.18632/oncotarget.8529.
37. Cardillo TM, Mostafa AA, Rossi DL, Liu D, Chang CH, Sharkey RM, and Goldenberg, DM. Treatment of high Trop-2-expressing triple-negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51. Cancer Res. 2017;77(abstract):3193.
38. Bardia A, Mayer IA, Diamond JR, Moroose RL, Isakoff SJ, Starodub AN, Shah NC, O’Shaughnessy J, Kalinsky K, Guarino M, et al. Efficacy and safety of anti-Trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer. J Clin Oncol. 2017;35:2141–48. doi:10.1200/JCO.2016.70.8297.
39. Gray JE, Heist RS, Starodub AN, Camidge DR, Kio EA, Masters GA, Purcell WT, Guarino MJ, Misleh J, Schneider CJ, et al. Therapy of small cell lung cancer (SCLC) with a topoisomerase-I-inhibiting antibody-drug conjugate (ADC) targeting Trop-2, sacituzumab govitecan. Clin Cancer Res. 2017;23:5711–19. doi:10.1158/1078-0432.CCR-17-0933.
40. Heist RS, Guarino MJ, Masters G, Purcell WT, Starodub AN, Horn L, Scheff RJ, Bardia A, Messersmith WA, Berlin J, et al. Therapy of advanced non-small-cell lung cancer with an SN-38-anti-Trop-2 drug conjugate, sacituzumab govitecan. J Clin Oncol. 2017;35:2790–97. doi:10.1200/JCO.2016.72.1894.
41. Starodub AN, Ocean AJ, Shah MA, Guarino MJ, Picozzi VJ, Jr., Vahdat LT, Thomas SS, Govindan SV, Maliakal PP, Wegener WA, et al. First-in-human trial of a novel anti-Trop-2 antibody-SN-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors. Clin Cancer Res. 2015;21:3870–78. doi:10.1158/1078-0432.CCR-14-3321.
42. Staudacher AH, Brown MP. Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required? Br J Cancer. 2017(117):.1736–42
43. Morton CL, Wierdl M, Oliver L, Ma MK, Danks MK, Stewart CF, Eiseman JL, Potter PM. Activation of CPT-11 in mice: identification and analysis of a highly effective plasma esterase. Cancer Res. 2000;60:4206–10.
44. Xie R, Mathijssen RH, Sparreboom A, Verweij J, Karlsson MO. Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis. J Clin Oncol. 2002;20:3293–301. doi:10.1200/JCO.2002.11.073.
45. Ocean AJ, Starodub AN, Bardia A, Vahdat LT, Isakoff SJ, Guarino M, Messersmith WA, Picozzi VJ, Mayer IA, Wegener WA, et al. Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: safety and pharmacokinetics. Cancer. 2017;123:3843–54. doi:10.1002/cncr.30789.
46. Stein A, Voigt W, Jordan K. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol. 2010;2:51–63. doi:10.1177/1758834009355164.
47. Zhao H, Lee C, Sai P, Choe YH, Boro M, Pendri A, Guan S, Greenwald RB. 20-O-acylcamptothecin derivatives: evidence for lactone stabilization 1. J Org Chem. 2000;65:4601–06.
48. Sharkey RM, Govindan SV, Cardillo TM, Donnell J, Xia J, Rossi EA, Chang C-H, Goldenberg DM. Selective and concentrated accretion of SN-38 with a CEACAM5-targeting antibody-drug conjugate (ADC), labetuzumab govitecan (IMMU-130). Mol Cancer Ther. 2018;17:196–203. doi:10.1158/1535-7163.MCT-17-0442.
49. Xie R, Mathijssen RH, Sparreboom A, Verweij J, Karlsson MO. Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea. Clin Pharmacol Ther. 2002;72:265–75.
50. Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, O’Shaughnessy, J, Moroose, RL, Santin, AD, Abramson, VG, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. N Engl J Med. 2019;380:741–51.
51. Bardia A, Tolaney SM, Juric D, Mayer IA, Vahdat LT, Diamond JR, Kalinsky K, O'Shaughnessy J, Moroose RL, Wahskowitz S. Efficacy of sacituzumab govitecan (anti-Trop-2-SN-38 antibody-drug conjugate) for endocrine-refractory hormone-receptor positive (HR+) metastatic breast cancer (mBC). J Clin Oncol. 2018;36(Abstr):1004.
52. Faltas B, Goldenberg DM, Ocean AJ, Govindan SV, Wilhelm F, Sharkey RM, Hajdenberg, J, Hodes, G, Nanus, DM, Tagawa, ST. Sacituzumab govitecan, a novel antibody-drug conjugate, in patients with metastatic platinum-resistant urothelial carcinoma. Clin Genitourin Cancer. 2016;14:e75–9.
53. Tagawa ST, Faltas B, Lam ET, Saylor P, Bardia A, JHajdenberg J, Morgans, AK, Lim, EA, Kalinsky, K, Simpson, PS, et al. Sacituzumab govitecan (IMMU-132) in patients with previously treated metastatic urothelial cancers (mUC): results from a Phase I/II study. J Clin Oncol. 2019;37(abst):354.
54. Tagawa ST, Petrylak DP, Grivas P, Agarwal N, Sternberg CN, Hernandez C, Siemon-Hryczyk P, Goswami T, Loriot Y. TROPHY-U-01: A phase II open-label study of sacituzumab govitecan (IMMU-132) in patients with advanced urothelial cancer after progression on platinum-based chemotherapy and/or anti-PD-1/PD-L1 checkpoint inhibitor therapy. (suppl). J Clin Oncol. 2019;37:abstrTPS3153.
55. Strop P, Tran TT, Dorywalska M, Delaria K, Dushin R, Wong OK, Ho, WH, Zhou, D, Wu, A, Kraynov, E, et al. RN927C, a site-specific Trop-2 antibody-drug conjugate (ADC) with enhanced stability, is highly efficacious in preclinical solid tumor models. Mol Cancer Ther. 2016;15:2698–708.
56. King GT, Eaton KD, Beagle BR, Zopf CJ, Wong GY, Krupka HI, Hua, SY, Messersmith, WA, and El-Khoueiry, AB. A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors. Invest New Drugs. 2018;36:836–47.
57. Tang W, Huang X, Ou Z, Yan H, Gan J, Dong Q, Tan, B, Yang, Y, Guo, Y, Li, S, et al. 2019. BAT8003, a potent anti-Trop-2 antibody-drug conjugate, for the treatment of triple negative breast cancer [abstract]. Cancer Res. 79(Issue 4). (suppl; In: The Proceedings of the 2018 San Antonio Breast Cancer Symposium, 2018): Abstractnr P6-20-16
58. Okajima D, Yasuda S, Yokouchi Y, Fujitani T, Sakurai K, Yamaguchi J, Kitamura, M, Terauchi, T, Shibutani, T, Aida, T, et al. Preclinical efficacy studies of DS-1062a, a novel TROP2-targeting antibody-drug conjugate with a novel DNA topoisomerase I inhibitor DXd. J Clin Oncol (Suppl). 2018;36(abstract):e24206.
59. Ogitani Y, Aida T, Hagihara K, Yamaguchi J, Ishii C, Harada N, Soma M, Okamoto H, Oitate M, Arakawa S, et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res. 2016;22:5097–108.
60. Nakada T, Sugihara K, Jikoh T, Abe Y, Agatsuma T. The latest research and development into the antibody-drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy. Chem Pharm Bull (Tokyo). 2019;67:173–85.
61. Sands JM, Shimizu T, Garon EB, Greenberg J, Guevara FM, Heist RS, Kobayashi, F, Noguchi, Y, Okajima, D, Tajima, N, et al. First-in-human phase 1 study of DR-1062a in patients with advanced solid tumors. J Clin Oncol (Suppl). 2019;37(abstr):9051.
62. Brennan J, Daiichi Sankyo presents preliminary phase 1 data for TROP2 targeting ADC DS-1062 in patients with non-small cell lung cancer at 2019. ASCO annual meeting 2019; Chicago, IL.
63. Doi T, Shitara K, Naito Y, Shimomura A, Fujiwara Y, Yonemori K, Shimizu, C, Shimoi, T, Kuboki, Y, Matsubara, N, et al. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. Lancet Oncol. 2017;18:1512–22.
64. Iwata TN, Ishii C, Ishida S, Ogitani Y, Wada T, Agatsuma T. A HER2-targeting antibody-drug conjugate, trastuzumab deruxtecan (DS-8201a), enhances antitumor immunity in a mouse model. Mol Cancer Ther. 2018;17:1494–503.
65. Ogitani Y, Hagihara K, Oitate M, Naito H, Agatsuma T. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016;107:1039–46.
66. Takegawa N, Nonagase Y, Yonesaka K, Sakai K, Maenishi O, Ogitani Y, Tamura, T, Nishio, K, Nakagawa, K, and Tsurutani, J. DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance. Int J Cancer. 2017;141:1682–89.
67. Cardillo TM, Sharkey RM, Rossi DL, Arrojo R, Mostafa AA, Goldenberg DM. Synthetic lethality exploitation by an anti-Trop-2-SN-38 antibody-drug conjugate, IMMU-132, plus PARP inhibitors in BRCA1/2-wild-type triple-negative breast cancer. Clin Cancer Res. 2017;23:3405–15. doi:10.1158/1078-0432.CCR-16-2401.